Helix Immuno-Oncology (formerly: Helix Polska) is a subsidiary of the Canadian biopharmaceutical company Helix BioPharma, established in 2013. Helix Immuno-Oncology (formerly: Helix Polska) is based in Warsaw, and the company is headed by a strong management team specialising in biotechnology and life science. Polish scientists participate in the development of original technologies in cancer therapy and support research on oncological drugs conducted in Poland, Canada and the USA.
Helix actively develops innovative products for cancer immunotherapy based on proprietary proprietary technologies. The company's drug development initiatives are based on technology platform: V-DOS47. This innovation is used in the treatment of malignant solid tumors.
Helix Immuno-Oncology is a biotechnology company with global competence. Helix Immuno-Oncology (formerly: Helix Polska) is based in Warsaw, while Helix BioPharma is headquartered in Toronto, Canada. Helix BioPharma is currently listed on the Toronto Stock Exchange. The Company actively cooperates with oncological clinics and research centres in Canada, the USA and Poland.
Helix BioPharma's research is conducted in cooperation with an international group of scientists - specialists of the highest competence in Poland and abroad.
